Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.41 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700040 | 1.00 | KMT2A (0.45) | KMT2AMEN1LMNAALDH1A1POLB | |
| SCHEMBL3702371 | 0.89 | POLB (0.45) | KMT2AMEN1LMNAALDH1A1POLB | |
| SCHEMBL7614061 | 0.89 | POLB (0.45) | KMT2AMEN1LMNAALDH1A1POLB | |
| SCHEMBL3692412 | 0.89 | RAB9A (0.48) | KMT2AMEN1NPC1RAB9APRSS1 | |
| SCHEMBL7610226 | 0.89 | RAB9A (0.48) | KMT2AMEN1NPC1RAB9APRSS1 | |
| SCHEMBL5020124 | 0.84 | CTSL (0.53) | L3MBTL1RAB9ACTSG | |
| SCHEMBL3700091 | 0.84 | CTSL (0.53) | L3MBTL1RAB9ACTSG | |
| SCHEMBL7615422 | 0.83 | HDAC3 (0.44) | KMT2AMEN1LMNAALDH1A1POLB | |
| SCHEMBL5020065 | 0.83 | KMT2A (0.49) | KMT2AMEN1LMNAALDH1A1POLB | |
| SCHEMBL11318126 | 0.83 | CTSL (0.51) | KMT2AMEN1LMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140121202-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8624052-B2 | S-t-butyl protected cysteine di-peptide analogs and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| WO-2012065102-A2 | S-T-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122792-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121202-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | CSTB, IAPP, VIP | KMT2A 4171/4885MEN1 1196/4885LMNA 4012/4885 |
| US-20120122792-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | CSTB, IAPP, VIP | KMT2A 4171/4885MEN1 1196/4885LMNA 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.